Otsuka Holdings Co., Ltd.

4578

JP3188220002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 18/06/2024 am IST			5-day change	1st Jan Change
6,274 ^JPY	+0.27%		-4.66%	+18.62%

07/06	Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026	CI
30/05	Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials	MT

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

June 07, 2024 at 09:30 am IST

Otsuka Holdings Co., Ltd. provided earnings guidance for the year 2026. For the year, the company expects Revenue of JPY 22,000 million, EPS of JPY 380 and Business profit of JPY 2,700 million.

Latest news about Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026	07/06	CI
Correction: Otsuka Pharmaceutical's PTSD Treatment Candidate Sees Statistically Significant Results in Two Out of Three Trials	30/05	MT
Japanese Shares Close Lower as JGB Yields Hit 12-Year High	29/05	MT
Otsuka Pharmaceutical's PTSD Treatment Candidate Fails to Meet Primary Endpoint in Phase 3 Trial	29/05	MT
Jefferies Adjusts Otsuka Holdings' Price Target to 7,800 Yen From 7,400 Yen, Keeps at Buy	23/05	MT
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1	22/05	MT
Otsuka to stop development of Alzheimer's disease drug	22/05	RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year Ending December 2024	22/05	CI
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	20/05	MT
Otsuka Holdings' Attributable Profit Jumps 26% in Q1	30/04	MT
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of 2024	30/04	CI
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	30/04	CI
Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation	29/04	MT
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04	MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	29/03	MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03	MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy	18/03	MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18/03	MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	07/03	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	26/02	DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16/02	MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	16/02	CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	16/02	CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	14/02	CI
Otsuka Holdings Lowers 2023 Profit Outlook	13/02	MT

Chart Otsuka Holdings Co., Ltd.

Duration

Period

More charts

Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),

Sector

Pharmaceuticals

Calendar

27/06/2024 - Détachement de for dividende intermédiaire

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Otsuka Holdings Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,257 JPY

Average target price

6,473 JPY

Spread / Average Target

+3.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
OTSUKA HOLDINGS CO., LTD.	+18.62%	21.51B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.54B
SANDOZ GROUP AG	+18.33%	15.34B
CIPLA LIMITED	+26.36%	15.12B
ZYDUS LIFESCIENCES LIMITED	+56.55%	13.37B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-14.94%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.36B
KRKA, D. D.	+27.27%	4.63B

Generic Pharmaceuticals